Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Actual. osteol ; 17(2): 92-103, 2021. ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1370258

ABSTRACT

El carcinoma paratiroideo (CP) es una neoplasia maligna con una incidencia de 0,015 cada 100.000 habitantes por año. Representa el 1% de los diagnósticos de hiperparatiroidismo primario y se manifiesta entre la 4.a y 5.a década de la vida, con una incidencia similar entre hombres y mujeres. La etiología del CP es incierta, ha sido asociada a formas esporádicas o familiares. Está caracterizado por altos niveles séricos de calcio y PTH y el desafío clínico-quirúrgico es el diagnóstico diferencial con otras entidades benignas como el adenoma o la hiperplasia de paratiroides. Aunque el diagnóstico de certeza es anatomopatológico, la sospecha clínica y el uso de métodos de baja complejidad (ecografía) con operadores avezados permite una correcta localización y abordaje pertinente del paciente para dirigir el tratamiento quirúrgico adecuado (resección en bloque) evitando persistencias y recurrencias de enfermedad. Se presenta el caso clínico de un paciente masculino que ingresa por síndrome de impregnación asociado a hipercalcemia, su abordaje diagnóstico, tratamiento y manejo interdisciplinario con discusión y revisión bibliográfica. (AU)


Parathyroid carcinoma (CP) is a malignant disease with an incidence of 0.015 per 100,000 inhabitants per year. It accounts for 1% of primary hyperparathyroidism diagnoses and occurs between the 4th and 5th decade of life, with a similar incidence between men and women. The etiology of CP is uncertain and has been associated with sporadic or family forms. CP is characterized by high serum calcium and PTH levels and the clinical-surgical challenge is the differential diagnosis with other benign entities such as parathyroid adenoma or hyperplasia. Although the diagnosis of certainty is achieved by pathological anatomy examination, the clinical suspicion and the use of low complexity methods (ultrasound) by experienced operators allows a correct localization and a patient-specific approach to direct the appropriate surgical treatment (block resection), avoiding persistence and recurrences of disease. The clinical case of a male patient admitted for severe hypercalcemia with multiple organ disfunction, the diagnostic approaches, treatment, and interdisciplinary management, together with review and discussion of the current literature are presented. (AU)


Subject(s)
Humans , Male , Middle Aged , Parathyroid Neoplasms/complications , Parathyroid Neoplasms/etiology , Parathyroid Neoplasms/diagnostic imaging , Hyperparathyroidism, Primary/complications , Hyperparathyroidism, Primary/diagnosis , Hyperparathyroidism, Primary/etiology , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Parathyroid Neoplasms/pathology , Calcitriol/administration & dosage , Calcium Gluconate/administration & dosage , Radiography , Tomography , Calcium/administration & dosage , Ultrasonography , Diagnosis, Differential , Hypercalcemia/blood
2.
Actual. osteol ; 16(1): 77-82, Ene - abr. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1140152

ABSTRACT

Introducción. El hipoparatiroidismo es una enfermedad caracterizada por la ausencia o concentraciones inadecuadamente bajas de hormona paratiroidea (PTH), que conduce a hipocalcemia, hiperfosfatemia y excreción fraccional elevada de calcio en la orina. Las calcificaciones del sistema nervioso central son un hallazgo frecuente en estos pacientes. Caso clínico. Mujer de 56 años con antecedente de hipotiroidismo, que ingresó por un cuadro de 6 días de evolución caracterizado por astenia, parestesias periorales y movimientos anormales de manos y pies. Las pruebas de laboratorio demostraron hipocalcemia, hiperfosfatemia y niveles bajos de hormona paratiroidea. Se realizó una tomografía computarizada de cráneo que mostró áreas bilaterales y simétricas de calcificaciones en hemisferios cerebelosos, ganglios basales y corona radiata. No se evidenciaron trastornos en el metabolismo del cobre y hierro. Se estableció el diagnóstico del síndrome de Fahr secundario a hipoparatiroidismo y se inició tratamiento con suplementos de calcio y vitamina D con evolución satisfactoria. Discusión. El síndrome de Fahr es un trastorno neurológico caracterizado por el depósito anormal de calcio en áreas del cerebro que controlan la actividad motora. Se asocia a varias enfermedades, especialmente, hipoparatiroidismo. La suplementación con calcio y vitamina D con el objetivo de normalizar los niveles plasmáticos de estos cationes es el tratamiento convencional. (AU)


Introduction. Hypoparathyroidism is a disease characterized by absence or inappropriately low concentrations of circulating parathyroid hormone, leading to hypocalcaemia, hyperphosphataemia and elevated fractional excretion of calcium in the urine. Central nervous system calcifications are a common finding in these patients. Case report. 56-year-old woman with a history of hypothyroidism who was admitted for a 6-day course of illness characterized by asthenia, perioral paresthesias, and abnormal movements of the hands and feet. Laboratory tests showed hypocalcemia, hyperphosphatemia, and low parathyroid hormone levels. A cranial computed tomography was performed. It showed bilateral and symmetrical areas of calcifications in the cerebellar hemispheres, basal ganglia, and radiata crown. No disorders of copper or iron metabolism were evident. The diagnosis of Fahr syndrome secondary to hypoparathyroidism was established and treatment with calcium and vitamin D supplements was started with satisfactory evolution. Discussion. Fahr's syndrome is a neurological disorder associated with abnormal calcium deposition in areas of the brain that control motor activity. It is associated with various diseases, especially hypoparathyroidism. The conventional treatment is supplementation with calcium and vitamin D, with the aim of normalizing their plasma levels. (AU)


Subject(s)
Humans , Female , Middle Aged , Calcinosis/diagnostic imaging , Hypoparathyroidism/diagnosis , Nervous System Diseases/diagnostic imaging , Parathyroid Hormone/blood , Calcinosis/complications , Calcinosis/drug therapy , Calcitriol/administration & dosage , Calcium Carbonate/administration & dosage , Calcium Gluconate/administration & dosage , Calcium/administration & dosage , Hyperphosphatemia/blood , Hypocalcemia/blood , Hypoparathyroidism/etiology , Hypoparathyroidism/drug therapy , Nervous System Diseases/complications , Nervous System Diseases/drug therapy
3.
Actual. osteol ; 13(3): 243-250, Sept - DIc. 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-1117571

ABSTRACT

La hipercalcemia es un trastorno común que representa aproximadamente el 0,6% de todas las admisiones médicas agudas. El hiperparatiroidismo primario (HPTP) y las neoplasias malignas son las dos causas más comunes de elevación de los niveles séricos de calcio; constituyen, en conjunto, alrededor del 90% de todos los casos. La presentación sintomática clásica de la hipercalcemia se observa con relativa poca frecuencia en el mundo desarrollado; la presentación más común es la detección asintomática en las pruebas bioquímicas. Sin embargo, en casos raros, el HPTP puede desarrollar hipercalcemia aguda, grave y sintomática, llamada crisis hipercalcémica (CH). Esta condición se asocia a alteraciones profundas en el estado mental y las funciones cardíaca, renal y gastrointestinal en presencia de concentraciones marcadamente elevadas de calcio sérico y paratohormona (PTH). Mientras que algunas elevaciones en el calcio sérico pueden ser bien toleradas, los síntomas de la CH son severos. Si el tratamiento se retrasa, la CH puede provocar la muerte. Describimos el caso de un paciente masculino que ingresa en la unidad de cuidados críticos por una CH secundaria a un HPTP por adenoma paratiroideo. (AU)


Hypercalcaemia is a most common disorder, accounting for approximately 0,6% of all acute medical admissions. Primary hyperparathyroidism (PHPT) and malignancy are the two most common causes of increased serum calcium levels, together accounting for about 90% of all cases. The classical symptomatic presentation of hypercalcaemia is seen relatively rarely in the developed world, the most common presentation being asymptomatic and detected following on biochemical testing. However, in rare cases HPTP can result in acute, severe and symptomatic hypercalcemia, called hypercalcemic crisis (HC). This condition is associated with profound disturbances in mental status, and cardiac, renal, and gastrointestinal function in the presence of markedly increased serum calcium and parathyroid hormone (PTH) concentrations. While some elevations in serum calcium can be well tolerated, symptoms of HC are severe. If treatment is delayed, HC can result in death. We describe herein a case of a male patient who was admitted to the intensive care unit as a consequence of HC resulting from elevated PTH, secondary to a parathyroid adenoma. We describe the case of a male patient who was admitted to the critical care unit for a HC mediated by PTH secondary to a parathyroid adenoma. (AU)


Subject(s)
Humans , Male , Middle Aged , Parathyroid Neoplasms/complications , Parathyroid Glands/pathology , Hyperparathyroidism, Primary/complications , Hypercalcemia/chemically induced , Parathyroid Hormone/metabolism , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Glands/surgery , Vitamin D Deficiency/blood , Calcitriol/administration & dosage , Calcium Gluconate/administration & dosage , Weight Loss , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Calcium/administration & dosage , Calcium/blood , Renal Dialysis , Cholecalciferol/administration & dosage , Dehydration , Diuretics/administration & dosage , Hyperparathyroidism, Primary/surgery , Hyperparathyroidism, Primary/diagnosis , Cinacalcet/administration & dosage , Pamidronate/administration & dosage , Crystalloid Solutions/administration & dosage , Hypercalcemia/diagnosis , Hypercalcemia/drug therapy , Hypercalcemia/blood
4.
Medical Journal of Tabriz University of Medical Sciences and Health Services. 2017; 38 (6): 56-59
in Persian | IMEMR | ID: emr-187553

ABSTRACT

Background and Objectives: Vitiligo is an acquired disease due to progressive lack of performance of melanocytes and appears as ring depigmentated patches and macules. About%2 of people are involved and because of unpleasant appearance, it creates emotional stress on patients .So new and better treatments are needed. This study was conducted to compare effectiveness of topical tacrolimus with topical calcipotriol in pigmentation of vitiligo patients


Materials and Methods:This study was done in double-blind randomized clinical trial on patients facial and hand vitiligo with under%20 involvement of body surface. Patients were categorized in two groups with tacrolimus and calcipotriol treatments and were evaluated and followed up for 12 months


Results: In statistical analysis, there was no significant difference between the effects of both dings on progression of pigmentation, but their on facial vitiligo was better than hand vitiligo [p=0.04].Side effects of treatment in both groups were mild and no serious side effects were reported, but Tacrolimus had significantly minimal side effects rather than Calcipotriol [p=0.02]


Conclusions: In this study,efficacy of topical tacrolimus was better than topical calcipotriol on face and efficacy of calcipotriol was better than tacrolimus on hand vitiligo


Subject(s)
Humans , Administration, Topical , Face , Hand , Tacrolimus/administration & dosage , Calcitriol/administration & dosage , Inpatients , Double-Blind Method
6.
Rev. chil. pediatr ; 84(6): 672-680, dic. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-703291

ABSTRACT

Introducción: La hipocalcemia es un hallazgo infrecuente en los pacientes atendidos en los servicios de urgencia pediátricos. El raquitismo se puede presentar como una hipocalcemia crónica la mayoría de las veces asintomática, sin embargo, algunos pacientes presentan tetanias hipocalcémica. Objetivo: Presentar el caso clínico de una niña con raquitismo hipocalcémico, cuyo diagnóstico fue tardío. Caso clínico: Prescolar de 2 años 5 meses con alteración en la marcha, mal incremento ponderal, espasmos musculares y signos de raquitismo activo. Los exámenes revelaron hipocalcemia severa, normofosfemia, fosfatasa alcalina y PTH elevada y niveles normales de 25 hidroxivitamina D. Se manejó con calcio y calcitriol, y se diagnosticó raquitismo vitamina D dependiente tipo I. Conclusión: Los síntomas y signos clásicos de raquitismo, así como la hipocalcemia, deben hacernos plantear hoy en día el diagnóstico de raquitismo. Un mejor conocimiento de esta patología permitirá evitar el retraso en el diagnóstico y un tratamiento más oportuno.


Introduction: Hypocalcemia is rare in patients attending pediatric emergency services. Rickets can present as a chronic hypocalcemia often asymptomatic, poor growth rate, psychomotor delay and bone abnormalities, but some patients may present tetanic seizures. Although its incidence has decreased, a resurgence of rickets has been described. Objective: To present a case of a child with hypocalcemic rickets, whose diagnosis was delayed. Case report: Preschool of 2,4 years old with gait disturbance, poor growth rate, muscle spams and signs of active rickets. Laboratory results showed hypocalcemia, normophosphemia, alkaline phosphatase, high PTH and normal 25-hydroxyvitamin D levels. She received treatment with calcium and calcitriol and had a good response; Vitamin D dependent rickets type I was diagnosed. Conclusion: Classics signs and symptoms of rickets, as hypocalcemic manifestations, should lead us today to diagnose rickets. Better knowledge of this disease will avoid retarded diagnosis and give a suitable treatment.


Subject(s)
Humans , Female , Child, Preschool , Hypocalcemia/diagnosis , Rickets/diagnosis , Clinical Evolution , Calcium/administration & dosage , Calcitriol/administration & dosage , Calcitriol/deficiency , Diagnosis, Differential , Hypocalcemia/drug therapy , Rickets/drug therapy
7.
Article in English | WPRIM | ID: wpr-93085

ABSTRACT

BACKGROUND/AIMS: This study was performed to compare the mucosal findings after esophagogastroduodenoscopy in two groups before and after the use of alendronate only and following administration of the enteric-coated alendronate (5 mg) and calcitriol (0.5 microg) combined drug (Maxmarvil, Yuyu Co.). METHODS: The study population consisted of 33 postmenopausal healthy female volunteers, aged 50 to 70 years (mean age, 58 +/- 5) without gastrointestinal symptoms and with normal baseline endoscopic findings. Esophagogastroduodenoscopy was performed at baseline and was repeated 2 weeks later after daily intake of Maxmarvil (n = 17 subjects) or alendronate only (n = 16 subjects). Mucosal injury scores were reported by an endoscopist after 2 weeks of treatment with each medication schedule. RESULTS: Esophageal mucosal injuries developed in two of 16 subjects in the alendronate only group and 0 of 17 in the Maxmarvil group. Gastric mucosal injuries developed in eight subjects in the alendronate group and four subjects in the Maxmarvil group; this difference was statistically significant. CONCLUSIONS: The mucosal damage scores for the alendronate group (total score 24) were significantly higher than those for the Maxmarvil group (total score 9) in the esophagus and stomach. Therefore, this study suggested that enteric-coated Maxmarvil is less harmful to gastrointestinal mucosa than alendronate, and may improve the tolerability of osteoporosis medication in clinical practice.


Subject(s)
Aged , Female , Humans , Middle Aged , Administration, Oral , Age Factors , Alendronate/administration & dosage , Bone Density Conservation Agents/administration & dosage , Calcitriol/administration & dosage , Drug Combinations , Endoscopy, Digestive System , Esophagus/drug effects , Gastric Mucosa/drug effects , Postmenopause , Predictive Value of Tests , Republic of Korea , Sex Factors , Tablets, Enteric-Coated , Time Factors , Treatment Outcome , Vitamins/administration & dosage
8.
West Indian med. j ; West Indian med. j;61(9): 928-931, Dec. 2012.
Article in English | LILACS | ID: lil-694369

ABSTRACT

We report for the first time the case of a young man who developed both glucocorticoid resistance and resistance to parathyroid hormone. Treatment with high doses of dexamethasone together with administration of calcium and calcitriol resulted in a significant improvement in the patient's condition. In this paper, we discuss in detail diagnostic and treatment strategies used on the patient and the impact on the course and outcome of both disorders. We associate the development of both these disorders with a possible inherited defect in the signal pathways common to glucocorticoid and parathyroid hormone receptors.


Por primera vez se reporta el caso de un joven que desarrolló resistencia a glucocorticoides y resistencia a la hormona paratiroidea. El tratamiento con altas dosis de dexametasona, junto con la administración de calcio y calcitriol, trajo como resultado una mejoría significativa de la condición del paciente. En este papel, se analiza en detalle el diagnóstico así como las estrategias de tratamiento del paciente, y su impacto en el curso y resultado de ambos trastornos. Se concluye que el desarrollo de ambos trastornos se halla asociado a un posible defecto hereditario en las vías de transducción de señales comunes a los receptores de las hormonas glucocorticoides y las hormonas paratiroideas.


Subject(s)
Adult , Child , Humans , Male , Metabolism, Inborn Errors/genetics , Parathyroid Hormone/administration & dosage , Pseudohypoparathyroidism/diagnosis , Calcitriol/administration & dosage , Calcium Carbonate/administration & dosage , Dexamethasone/administration & dosage , Diagnosis, Differential , Drug Resistance , Drug Therapy, Combination , Phenotype , Pseudohypoparathyroidism/drug therapy , Pseudohypoparathyroidism/genetics , Receptors, Glucocorticoid/deficiency , Receptors, Glucocorticoid/genetics
9.
Rev. salud pública ; Rev. salud pública;13(5): 804-813, oct. 2011. ilus, tab
Article in English | LILACS | ID: lil-625646

ABSTRACT

Objective Hypocalcaemia is a frequently arising complication following total thyroidectomy. Routine postoperative prophylactic administration of vitamin D or metabolites and calcium reduce the incidence of symptomatic hypocalcaemia; this article reports evaluating its cost-effectiveness in Colombia. Methods Meta-analysis was used for comparing the administration of vitamin D or metabolites to oral calcium or no treatment at all in patients following total thyroidectomy and a cost-effectiveness analysis was designed based on a decision-tree model with local costs. Results The OR value for the comparison between calcitriol and calcium compared to no treatment and to exclusive calcium treatment groups was 0.32 (0.13-0.79 95 %CI) and 0.31 (0.14-0.70 95 %CI), respectively. The most cost-effective strategy was vitamin D or metabolites and calcium administration, having a US $0.05 incremental cost-effectiveness ratio. Conclusion Prophylactic treatment of hypocalcaemia with vitamin D or metabolites + calcium or calcium alone is a cost-effective strategy.


Objetivos La hipo calcemia es la complicación más frecuente después de tiroidectomía. La administración profiláctica de vitamina D o metabolitos y calcio reduce la incidencia de hipocalcémia sintomática. Se evalúa su costo-efectividad en Colombia. Materiales y métodos Utilizamos la información de un meta-análisis que comparó la administración de vitamina D o metabolitos contra calcio no tratamiento en pacientes llevados a tiroidectomía total y diseñamos un análisis de costo-efectividad basados en un modelos de decisiones con costos locales. Resultados El valor del OR para la comparación entre calcitriol y calcio comparado con no tratamiento o calcio exclusivo fue de 0.32 (95 % IC, 0.13- 0.79) y 0.31 (95 % IC, 0.14-0.70), respectivamente. La estrategia más costo-efectiva fue la administración de vitamina D o metabolitos y calcio, con una relación de costo-efectividad incremental de US $0.05. Conclusiones El tratamiento profiláctico de la hipo calcemia con vitamina D o metabolitos y calcio o calcio exclusivo después de tiroidectomía total es una estrategia costo-efectiva.


Subject(s)
Humans , Calcitriol/therapeutic use , Calcium Carbonate/therapeutic use , Calcium Gluconate/therapeutic use , Hypocalcemia/prevention & control , Postoperative Care/economics , Postoperative Complications/prevention & control , Thyroidectomy , Calcitriol/administration & dosage , Calcitriol/economics , Calcium Carbonate/administration & dosage , Calcium Carbonate/economics , Calcium Gluconate/administration & dosage , Calcium Gluconate/economics , Calcium/blood , Colombia , Cost-Benefit Analysis , Decision Trees , Drug Costs , Emergencies/economics , Hypocalcemia/economics , Hypocalcemia/epidemiology , Hypocalcemia/etiology , Length of Stay/economics , Length of Stay/statistics & numerical data , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Probability , Tetany/epidemiology , Tetany/etiology , Tetany/prevention & control
11.
Rev. méd. Chile ; 131(7): 779-784, jul. 2003.
Article in Spanish | LILACS | ID: lil-356061

ABSTRACT

We report a 29 years old woman with a highly symptomatic primary hyperparathyroidism. After parathyroid adenoma excision, she presented a prolonged and life threatening hypocalcemia, due to a severe hungry bone syndrome. Conventional treatment with oral and intravenous calcium and calcitriol supplementation failed to raise serum and urinary calcium or to relief symptoms. After one month, we indicated a continuous intravenous calcium infusion allowing, during 6 months, an adequate outpatient management. Initial T scores for bone density were markedly low (L2-L4: -3.14; femoral neck: -3.07) and they increased 17 per cent after 18 days of calcium infusion. After 147 days of treatment bone density was normal, increasing by 61 per cent. The present case shows that the hungry bone syndrome can be a real risk for patients and a complex therapeutic challenge. With an appropriate calcium supply an early, fast and complete recovery of bone mass can be achieved.


Subject(s)
Humans , Female , Adult , Bone Diseases, Metabolic , Calcium/administration & dosage , Hypocalcemia/etiology , Bone Regeneration , Bone Diseases, Metabolic , Adenoma/complications , Adenoma/surgery , Calcitriol/administration & dosage , Bone Density , Alkaline Phosphatase/analysis , Hyperparathyroidism/complications , Hyperparathyroidism/surgery , Hypocalcemia/drug therapy , Infusions, Intravenous , Parathyroid Neoplasms/complications , Parathyroid Neoplasms/surgery , Syndrome
12.
Rev. méd. Chile ; 128(1): 80-5, ene. 2000. tab, graf
Article in Spanish | LILACS | ID: lil-258091

ABSTRACT

Hungry bone syndrome is a unusual complication of the postoperative period of primary hyperparathyroidism. This syndrome is characterized by hypocalcemia, hypophosphatemia and hypomagnesemia, due to an excessive bone remineralization. We report the clinical features, laboratory and therapy in four females (aged 39 to 73 years old) with a long standing hyperparathyroidism, elevated alkaline phosphatases and decreased bone mineralization in two. The mean size of the adenoma was 2.9 ñ 1.1 cm. Hypocalcemia appeared between days 1 and 6 of the postoperative period. All were treated with calcium, calcitriol and magnesium at different timing and dosages. The mean hospitalization period was 19.8 ñ 2.1 days. As reported previously, low bone mineralization and a large adenoma are risk factors for the syndrome. Serial monitoring of serum calcium and magnesium and an early supplementation of these minerals could prevent hypocalcemia and decrease the hospitalization time


Subject(s)
Humans , Female , Adult , Middle Aged , Parathyroid Neoplasms/surgery , Bone Resorption/physiopathology , Parathyroid Neoplasms/complications , Calcitriol/administration & dosage , Calcium/administration & dosage , Hypophosphatemia/diagnosis , Hypercalcemia/diagnosis , Bone Density
13.
Article in English | IMSEAR | ID: sea-45349

ABSTRACT

Sixty-one psoriasis patients, 46 males and 15 females (mean age: 40 years, range: 20-70 years) with baseline PASI score of 7.16 (+/- 3.66 SD) were enrolled in the study. All subjects were advised to apply calcipotriol ointment twice daily for 6 weeks. Six patients dropped out, five after 2 weeks and one after 4 weeks of treatment. PASI scores of fifty five patients were reduced to 2.16 per cent, 46.78 per cent and 55.55 per cent by 2 weeks, 4 weeks and 6 weeks respectively versus the baseline. Overall clinical assessment showed remission in 7.27 per cent marked improvement 74.54 per cent and slight improvement 18.18 per cent. Mild erythema were observed in fourteen patients (22.95%) that were mostly transient except for one patient. Serum creatinine, calcium and phosphate were normal throughout the study.


Subject(s)
Administration, Topical , Adult , Aged , Calcitriol/administration & dosage , Chronic Disease , Dermatologic Agents/administration & dosage , Female , Humans , Male , Middle Aged , Psoriasis/drug therapy , Severity of Illness Index , Thailand , Time Factors
16.
Medicina (B.Aires) ; Medicina (B.Aires);56(1): 59-62, ene.-feb. 1996. tab, graf
Article in Spanish | LILACS | ID: lil-163388

ABSTRACT

Se presenta el caso de un paciente en hemodiálisis crônica que desarrolla hiperparatiroidismo secundaria severo, incluyendo la presencia de un tumor pardo en el maxilar inferior. La terapeútica habituál implica cirugía local, radiaciones, esteroides y/o paratiroidectomía. Como alternativa y para obviar las posibles complicaciones de la cirugía, se suprimió la actividad paratiroidea mediante la administración de calcitriol oral en dosis crecientes -3,5 a 9 ug/semana- y carbonato de calcio. Luego de 19 meses de tratamiento se constato la desaparición del tumor y de todos los signos clínicos y radiológicos del hiperparatiroidismo.


Subject(s)
Humans , Male , Adult , Calcitriol/administration & dosage , Calcium Carbonate/administration & dosage , Mandibular Diseases/drug therapy , Granuloma, Giant Cell/drug therapy , Hyperparathyroidism, Secondary/drug therapy , Administration, Oral , Calcitriol/therapeutic use , Calcium Carbonate/therapeutic use , Mandibular Diseases/etiology , Granuloma, Giant Cell/etiology , Renal Dialysis , Hyperparathyroidism, Secondary/etiology , Renal Insufficiency, Chronic/complications , Parathyroid Hormone/blood , Parathyroidectomy
17.
Rev. mex. ortop. traumatol ; 9(6): 344-7, nov.-dic. 1995. tab, ilus
Article in Spanish | LILACS | ID: lil-180625

ABSTRACT

La osteoporosis es un padecimiento por disminución de la masa ósea por unidad de volumen, que compromete la competencia mecánica del esqueleto. Es debida a aumento de reabsorción ósea, a disminución de la formación de hueso o a una combinación de ambos procesos. Es inducida por múltiples factores. Su tratamiento involucra un proceso diagnóstico que determina primero la pérdida del componente óseo mineral y después el tipo de alteración del remodelamiento. A partir de esto, se decide el tipo de tratamiento a seguir, ya sea con formadores de hueso o con anti-reabsorbentes


Subject(s)
Osteoporosis/classification , Osteoporosis/therapy , Algorithms , Calcitriol/administration & dosage , Calcitonin/administration & dosage , Calcium/administration & dosage , Bone Density , Bone Remodeling
18.
Rev. chil. pediatr ; 64(4): 252-8, jul.-ago. 1993. tab, ilus
Article in Spanish | LILACS | ID: lil-125411

ABSTRACT

El raquitismo hipofosfatémico familiar (raquitismo hipofosfémico familiar) se caracteriza por alteración del transporte renal de fosfatos, hipofosfatemia difícil de tratar, raquitismo, normocalcemia y talla baja final. La hipofosfatemia se transmite por herencia dominante ligada al cromosoma X. El calcitriol 1,25 (OH)2 D3 plasmático es inapropiadamente bajo para la magnitud de la hipofosfatemia, por lo que se postula un defecto en su síntesis. El tratamiento incluye dosis orales altas de fosfato y calcitriol, a pesar de lo cual persiste la hipofosfatemia y tallas finales resultan bajas en la mayoría de los pacientes


Subject(s)
Humans , Child , Calcitriol/administration & dosage , Hypophosphatemia, Familial/drug therapy , Phosphates/administration & dosage , Rickets/drug therapy , Growth Disorders/etiology , Rickets/metabolism
19.
Acta physiol. pharmacol. latinoam ; 36(4): 397-402, 1986. ilus
Article in English | LILACS | ID: lil-44845

ABSTRACT

La administración oral de 0.5 ugm/d/100 gm de peso a ratas normales produjo una significativa despoblación de la médula ósea, especialmente en la línea eritroide. El análisis de muestras de sangre periférica mostró ligera anemia con reticulocitopenia. La tasa de desaparición de eritrocitos marcados con 51-cr no fue afectada por el tratamiento, lo que sugiere que éste impide que la médula ósea reponga los eritrocitos a la tasa normal. El efecto adverso del tratamiento sobre la eritropoyesis parece relacionado con el grado de hipercalcemia que, a su vez, depende del contenido de la dieta


Subject(s)
Rats , Animals , Calcitriol/pharmacology , Calcium/metabolism , Erythropoiesis/drug effects , Reticulocytes/analysis , Anemia/chemically induced , Calcitriol/administration & dosage , Diet , Bone Marrow/cytology , Rats, Mutant Strains
SELECTION OF CITATIONS
SEARCH DETAIL